Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.
Just days after rounding up $30 million in venture cash, New York-based Intercept Pharmaceuticals is boldly gambling that investors will cough up about $75 million to buy into a late-stage orphan drug for chronic liver disease. The biotech filed for an ambitious IPO, hoping it can avoid the price cuts that most other such development-stage biotech bids have been forced to endure in recent years.
Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea.
Boston Biomedical's focus on targeting cancer stem cells has paid off.
Chelsea Therapeutics ( $CHTP ) has racked up some more positive efficacy data for its lead drug droxidopa , which is now up for review at the FDA. Investigators reported the drug spurred a statistically
While the FDA reviews its application for approval of the experimental drug, Sunovion Pharmaceuticals revealed upbeat data from a major Phase III trial of its ciclesonide nasal aerosol against...
Japan's Dainippon Sumitomo is slapping down $15 million and promising up to $300 million more in milestones in exchange for the rights to Intercept Pharmaceuticals' late-stage liver disease drug in
The FDA has given the green light to Dainippon Sumitomo Pharma's Latuda ( lurasidone ), an atypical antipsychotic. The drug is designed to work like other atypcals such as Zyprexa, Risperdal or
Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion , the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the
With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.